A Phase 2/3 interventional study of cisplatin plus pemetrexed in Lung Neoplasms, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-07-20.
Sponsored by Fudan University · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing cisplatin in Adenocarcinoma of Lung — 2 open to participants now, 3 under way, 1 of them phase 3. Cisplatin · Adenocarcinoma of Lung.
Among the 15 studies testing cisplatin in Adenocarcinoma of Lung, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2018, is the only one in phase 2/3, and was the 14th registered.
418 studies on the registry are indexed under Adenocarcinoma of Lung; 79 are open to participants now.
Browse Adenocarcinoma of Lung studies →2 of the 15 studies testing cisplatin in Adenocarcinoma of Lung are open now, in 1 country. Recruiting first, the newest first:
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 19–70
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 58 Adenocarcinoma of Lung studies recruiting now, 36 (62%) set no upper age limit and 10 (17%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 14 · Phase 3 2
First in 1995; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 60 across 293 interventional studies indexed under Adenocarcinoma of Lung.
Median enrollment 116 across the 13 interventional studies. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 15 has an industry lead sponsor. The 10 most frequent:
Fudan University is the lead sponsor of 1,318 studies on the registry; 646 are open to participants now.
12 studies in Adenocarcinoma of Lung by Fudan University: 8 open now, 8 under way, 5 of them phase 3. Of 4 finished, 0 (0%) have results posted.
Among the 12 studies in Adenocarcinoma of Lung by Fudan University, this one is the only one that started in 2018, is the only one in phase 2/3, and was the 2nd registered.
Fudan University’s Adenocarcinoma of Lung studies by the year they started, since 2015.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing cisplatin in Adenocarcinoma of Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Fudan University’s 12 in Adenocarcinoma of Lung:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1004. Solid subtype, micropapillary subtype, vascular involvement, pleural involvement and low differentiation are high risk factors of post-operative recurrence for early-stage lung adenocarcinoma patients. The purpose of this clinical trial is to determine whether the widely used adjuvant chemotherapy strategy cisplatin/ pemetrexed is more effective than no further treatment for Stage pI lung adenocarcinoma patients with high post-operative recurrence risk - in terms of no dose related toxicities, premature treatment withdrawal or death.
Background:
Management of lung cancer varies according to the clinical and pathological stage. For stage I lung adenocarcinoma, radical surgery is the preferred initial treatment and adjuvant chemotherapy is usually not recommended due to a fine prognosis and relatively low post-operative recurrence rate. Still, a number of stage pI patients will suffer a relapse after surgery, among which are highly associated with solid subtype, micropapillary subtype, vascular involvement, pleural involvement and low differentiation. Recently, some retrospective researches have shown a significant survival benefit of adjuvant chemotherapy for such stage pI high-recurrent-risk patients, but there lacks evidence from prospective randomized clinical trails.
Objective:
Randomization:
Each of the patients enrolled will be recorded in the computer system. Blank randomization will be done using a digital randomization software, at least 1 week before the first time of chemotherapy or observation.
Prechemotherapy assessment: For all the patients enrolled, the postoperative physical or laboratory examination should be equally qualified no matter which group they will be in. For Group Adjuvant Chemotherapy patients, they will receive laboratory examinations before chemotherapy to test blood cells and liver function in consideration of safety as routine.
Follow up:
Patients will be followed up per 4 months for the first three years and each six months for the forth to fifth years during the research. Lung multi-detector row computed tomography (MDCT) and abdominal ultrasonography tests will be done twice a year; bone SPECT scan and enhanced brain MRI scan will be conducted per year routinely. Patients will be suggested to continue the annual follow-up after the research.
Main research variables:
Primary end point: Disease free survival in the two arms
Secondary endpoints:
This study is recognized in our institute as "Eastern Cooperative Thoracic Oncology Projects (ECTOP-1004)"
418 studies on the registry are indexed under Adenocarcinoma of Lung; 79 are open to participants now.
This study's planned enrollment of 300 is above the median of 60 across 293 interventional studies indexed under Adenocarcinoma of Lung.
Browse Adenocarcinoma of Lung studies →Fudan University is the lead sponsor of 1,318 studies on the registry; 646 are open to participants now.
Compared within Adenocarcinoma of Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: cisplatin 75mg/m2 iv Drug: pemetrexed 500mg/m2 iv
Drug: cisplatin plus pemetrexed
Observation and follow up only
Drug pages: Cisplatin · Pemetrexed
cisplatin 75mg/m2 iv; pemetrexed 500mg/m2 iv
Recurrence free survival (RFS)
from date of randomization until the date of showing signs of relapse, including evidence of medical image or pathology.
Time frame: up to 5 years
Overall survival (OS)
from date of randomization until the date of death from any cause, withdrawal of consent, or the end of the study.
Time frame: up to 5 years
Recurrence pattern
locoregional recurrence, metastatic recurrence, or both.
Time frame: up to 5 years
Quality of life
assessed with Eastern Cooperative Oncology Group-quality of life questionnaire(EORTC QLQ-C30/- LC13) scale. Discription of EORTC QLQ-C30/- LC13: The full name of the scale is Eastern Cooperative Oncology Group- quality of life questionnaire, including a core scale (EORTC QLQ-C30, version 3.0) and a module specified for lung cancer (EORTC QLQ- LC13). The scale is authorized by Quality of Life Department, EORTC Headquarters (Avenue E Mounier 83 - B11, 1200 Brussels BELGIUM) for scientific research. The scale ranges in score from 0 to 100. A higher score represents a a better health status.
Time frame: up to 5 years
Plan to share: Undecided
Started Jan 2018 (actual). Primary completion is estimated for Jan 2024, 72 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cisplatin · Pemetrexed